CN112245648A - Anti-inflammatory and antibacterial hydrocolloid oily yarn and preparation method thereof - Google Patents
Anti-inflammatory and antibacterial hydrocolloid oily yarn and preparation method thereof Download PDFInfo
- Publication number
- CN112245648A CN112245648A CN202011196428.XA CN202011196428A CN112245648A CN 112245648 A CN112245648 A CN 112245648A CN 202011196428 A CN202011196428 A CN 202011196428A CN 112245648 A CN112245648 A CN 112245648A
- Authority
- CN
- China
- Prior art keywords
- parts
- inflammatory
- hydrocolloid
- bacteriostatic
- oily yarn
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/28—Polysaccharides or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/20—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing organic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/24—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/40—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing ingredients of undetermined constitution or reaction products thereof, e.g. plant or animal extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/204—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with nitrogen-containing functional groups, e.g. aminoxides, nitriles, guanidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/21—Acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/23—Carbohydrates
- A61L2300/232—Monosaccharides, disaccharides, polysaccharides, lipopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/23—Carbohydrates
- A61L2300/236—Glycosaminoglycans, e.g. heparin, hyaluronic acid, chondroitin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
Abstract
The invention belongs to the technical field of medical instruments, and particularly relates to an anti-inflammatory and bacteriostatic hydrocolloid oily gauze and a preparation method thereof. The anti-inflammatory and bacteriostatic hydrocolloid oily yarn provided by the invention comprises the following raw materials in parts by weight: the base material is reticular polyester fiber; the hydrocolloid comprises the following components in parts by weight: 8-12 parts of thermoplastic elastomer, 30-50 parts of vaseline, 5-15 parts of lanolin, 200 parts of liquid paraffin, 10-25 parts of sodium carboxymethylcellulose, 2-8 parts of anti-inflammatory bacteriostatic agent and 5-15 parts of tissue repair agent. The anti-inflammatory and bacteriostatic hydrocolloid oily yarn provided by the invention has excellent air permeability, absorbability and viscosity, has good performance of being attached to skin, can resist bacteria, diminish inflammation, stop bleeding, inhibit the formation of scars, has obvious effect of promoting wound healing, and is safe and non-irritant.
Description
Technical Field
The invention belongs to the technical field of medical instruments, and particularly relates to an anti-inflammatory and bacteriostatic hydrocolloid oily gauze and a preparation method thereof.
Background
The medical dressing is a material for covering the wound surface and assisting the wound healing. The cotton gauze is the medical dressing with the largest production and use amount in China. From the in service behavior, cotton gauze cloth has higher imbibition ability, can make liquid evenly distributed in monoblock gauze, prevents the production of local hydrops, but cotton gauze is easy dry, still can bring very big misery for patient from some vital tissues under the wound surface adhesion when getting rid of. With the aging of socioeconomic and world population, traditional medical dressings represented by cotton gauze have difficulty meeting the requirements of the nursing process.
At present, many scholars have conducted intensive research on moist environment and wound healing, and have successively developed various novel functional medical dressings.
The hydrocolloid oily gauze is a dressing prepared by adding hydrocolloid particles into vaseline gauze, and can form gel after absorbing seepage, so that a moist wound environment is created, the hydrocolloid oily gauze is not adhered to a wound, the wound can be reduced, and the wound healing is promoted.
The hydrocolloid oily yarn in the market at present is made of vaseline, hydrocolloid particles and gauze, but does not have moisturizing, anti-inflammatory and bacteriostatic effects, so that the hydrocolloid oily yarn with anti-inflammatory and bacteriostatic effects is urgently needed.
Disclosure of Invention
In order to solve the problems in the prior art, the invention aims to provide an anti-inflammatory and bacteriostatic hydrocolloid oily yarn and a preparation method thereof. The hydrocolloid oily yarn with the anti-inflammatory and bacteriostatic functions has excellent air permeability, absorbability, viscosity and good skin bonding performance, and the added tissue repairing agent and the anti-inflammatory and bacteriostatic agent play roles in resisting bacteria and diminishing inflammation, stopping bleeding, promoting wound healing and inhibiting scar formation. The hydrocolloid oily gauze is especially suitable for various bruises, burns, bedsores and various surgical wounds.
In order to achieve the purpose, the invention provides the technical scheme that:
the invention provides an anti-inflammatory and bacteriostatic hydrocolloid oily yarn which is characterized by comprising a base material and a hydrocolloid component: the base material is reticular polyester fiber;
the hydrocolloid comprises the following components in parts by weight: 8-12 parts of thermoplastic elastomer, 30-50 parts of vaseline, 5-15 parts of lanolin, 200 parts of liquid paraffin, 10-25 parts of sodium carboxymethylcellulose, 2-8 parts of anti-inflammatory bacteriostatic agent and 5-15 parts of tissue repair agent.
Preferably, the tissue repair agent consists of allantoin, zinc hyaluronate and calcium hyaluronate in a weight ratio of (4-9): (2-5): (1-3).
Preferably, the tissue repair agent consists of allantoin, zinc hyaluronate and calcium hyaluronate in a weight ratio of 6:3: 1.
Preferably, the anti-inflammatory bacteriostatic agent consists of glucosamine, sodium ferulate and chitosan in a weight ratio of (1-3) to (2-7) to (4-9).
Preferably, the anti-inflammatory bacteriostatic agent consists of glucosamine, sodium ferulate and chitosan in a weight ratio of 2:3: 7.
Preferably, the thermoplastic elastomer is SEBS.
Preferably, the hydrocolloid comprises the following components in parts by weight: 10 parts of thermoplastic elastomer, 40 parts of vaseline, 10 parts of lanolin, 150 parts of liquid paraffin, 15 parts of sodium carboxymethylcellulose, 5 parts of anti-inflammatory bacteriostatic agent and 10 parts of tissue repair agent.
Preferably, the SEBS is selected from one or more of G1650, G1651 and G1652 of Kraton in the United states.
Preferably, the particle aperture of the sodium carboxymethyl cellulose is 20-150 μm.
The invention also provides the anti-inflammatory and bacteriostatic hydrocolloid oily yarn, which is characterized by comprising the following steps:
weighing the raw materials according to the weight parts of the hydrocolloid oily yarn;
softening the thermoplastic elastomer, the liquid paraffin, the vaseline and the lanolin for 25-45min at the temperature of 100-200 ℃ to obtain a mixture;
adding the sodium carboxymethylcellulose, the anti-inflammatory bacteriostatic agent and the tissue repair agent into the mixture, mixing and stirring at 90-125 ℃ to obtain a melt, and defoaming in vacuum;
and coating the melt after vacuum defoaming on the base material to obtain the hydrocolloid oily yarn.
The hydrocolloid oil gauze disclosed by the invention is added with a tissue repairing agent consisting of allantoin, zinc hyaluronate and calcium hyaluronate. The allantoin can promote cell growth, accelerate wound healing, promote tissue healing and cell metabolism, and is a good healing agent for skin wound. The invention unexpectedly discovers that when allantoin, zinc hyaluronate and calcium hyaluronate are combined into a tissue repair regulator according to the weight ratio of 6:3:1, the components have mutual synergistic effect, so that the wound skin tissue can be repaired, scar formation is inhibited, the hygroscopicity of the composition can be increased, a moist environment beneficial to wound healing can be provided for a wound, and the capability of absorbing biological fluid of the composition is enhanced.
The anti-inflammatory and bacteriostatic hydrocolloid oily gauze provided by the invention is added with an anti-inflammatory and bacteriostatic agent consisting of glucosamine, sodium ferulate and chitosan. Glucosamine can inhibit wound inflammation and relieve pain. Experiments prove that the anti-inflammatory bacteriostatic agent consisting of glucosamine, sodium ferulate and chitosan according to the weight ratio of 2:3:7 has the synergistic effect of the components, can effectively promote the medicine to permeate the skin, so that the hydrocolloid oily gauze provided by the invention can better exert the anti-inflammatory bacteriostatic effect and effectively inhibit the generation of harmful bacteria on the surface of the skin.
Compared with the prior art, the anti-inflammatory and bacteriostatic hydrocolloid oily yarn provided by the invention has the following advantages:
(2) the added tissue repairing agent of the anti-inflammatory and bacteriostatic hydrocolloid oily gauze provided by the invention plays roles in promoting wound healing, promoting tissue growth and inhibiting scar formation, and can provide a slightly humid environment beneficial to healing for a wound and enhance the liquid absorption capacity of the dressing; the healing time of the wound surface is obviously shortened, the adhesion between the wound and the dressing is prevented, the dressing change is painless, and the dressing change is free from irritation to the skin;
(3) the anti-inflammatory and bacteriostatic hydrocolloid oily yarn provided by the invention has the effects of resisting bacteria, diminishing inflammation and stopping bleeding by adding the anti-inflammatory and bacteriostatic agent, and can inhibit the breeding of harmful bacteria on the surface of skin.
Detailed Description
The present invention is further illustrated by the following description of specific embodiments, which are not intended to limit the invention, and various modifications and improvements can be made by those skilled in the art based on the basic idea of the invention, but the invention is within the protection scope of the invention.
SBES is a styrene-ethylene-butylene-styrene block copolymer available from Kraton, usa under code number G1651.
The starting materials in the examples of the present invention are all commercially available.
Example 1 an anti-inflammatory bacteriostatic hydrocolloid oily yarn
The embodiment provides a hydrocolloid oily yarn, and the concrete scheme is as follows:
a hydrocolloid oily yarn consisting of a substrate and a hydrocolloid component:
the base material is reticular polyester fiber,
the hydrocolloid component is prepared from the following raw materials in parts by weight:
16518 parts of G, 30 parts of vaseline, 5 parts of lanolin, 100 parts of liquid paraffin, 10 parts of sodium carboxymethylcellulose, 2 parts of an anti-inflammatory bacteriostatic agent and 5 parts of a tissue repair agent;
the tissue repair agent consists of allantoin, zinc hyaluronate and calcium hyaluronate according to the weight ratio of 6:3: 1.
The anti-inflammatory bacteriostatic agent consists of glucosamine, sodium ferulate and chitosan according to the weight ratio of 2:3: 7. The preparation method of the anti-inflammatory and bacteriostatic hydrocolloid oily yarn comprises the following steps:
weighing the raw materials in parts by weight;
softening 1651 of G, liquid paraffin, vaseline and lanolin in a reaction kettle at 200 deg.C for 30 min to obtain a mixture;
and adding the sodium carboxymethylcellulose, the anti-inflammatory bacteriostatic agent and the tissue repair agent into the mixture, wherein the particle aperture of the sodium carboxymethylcellulose is 60 microns. Mixing and stirring at the rotating speed of 100r/min for 20min at the temperature of 100 ℃ to obtain a melt, and defoaming in vacuum;
coating the melt after vacuum defoaming on the reticular polyester fiber to obtain a base material net;
the specific coating process comprises the following steps: the melt was placed in a thermostatic glue bath in a two-roll coater, the temperature in the glue bath being maintained at 100 ℃. The reticular polyester fiber passes through a first coating roller which is uniformly covered with a layer of melt and is coated with a layer of melt in advance; and removing redundant melt in the mesh holes in the reticular polyester fibers by a second coating roller to obtain the base material mesh. Wherein the spacing between the two rolls was 2mm and the coating speed was 4.5 m/min.
Cooling, laminating, cutting and packaging to obtain the hydrocolloid oily yarn.
Example 2 hydrocolloid oily yarn with anti-inflammatory and bacteriostatic effects
The embodiment provides a hydrocolloid oily yarn, and the concrete scheme is as follows:
a hydrocolloid oily yarn consisting of a substrate and a hydrocolloid component:
the base material is reticular polyester fiber,
the hydrocolloid component is prepared from the following raw materials in parts by weight:
165110 parts of G, 40 parts of vaseline, 10 parts of lanolin, 150 parts of liquid paraffin, 15 parts of sodium carboxymethylcellulose, 5 parts of an anti-inflammatory bacteriostatic agent and 10 parts of a tissue repair agent;
the tissue repair agent consists of allantoin, zinc hyaluronate and calcium hyaluronate according to the weight ratio of 6:3: 1.
The anti-inflammatory bacteriostatic agent consists of glucosamine, sodium ferulate and chitosan according to the weight ratio of 2:3: 7.
The preparation method of the anti-inflammatory and bacteriostatic hydrocolloid oily yarn comprises the following steps:
weighing the raw materials in parts by weight;
softening 1651 of G, liquid paraffin, vaseline and lanolin in a reaction kettle at 200 deg.C for 30 min to obtain a mixture;
and adding the sodium carboxymethylcellulose, the anti-inflammatory bacteriostatic agent and the tissue repair agent into the mixture, wherein the particle aperture of the sodium carboxymethylcellulose is 60 microns. Mixing and stirring at the rotating speed of 100r/min for 20min at the temperature of 100 ℃ to obtain a melt, and defoaming in vacuum;
coating the melt after vacuum defoaming on the reticular polyester fiber to obtain a base material net;
the specific coating process comprises the following steps: the melt was placed in a thermostatic glue bath in a two-roll coater, the temperature in the glue bath being maintained at 100 ℃. The reticular polyester fiber passes through a first coating roller which is uniformly covered with a layer of melt and is coated with a layer of melt in advance; and removing redundant melt in the mesh holes in the reticular polyester fibers by a second coating roller to obtain the base material mesh. Wherein the spacing between the two rolls was 2mm and the coating speed was 4.5 m/min.
Cooling, laminating, cutting and packaging to obtain the hydrocolloid oily yarn.
Example 3 hydrocolloid oily yarn with anti-inflammatory and bacteriostatic effects
The embodiment provides a hydrocolloid oily yarn, and the concrete scheme is as follows:
a hydrocolloid oily yarn consisting of a substrate and a hydrocolloid component:
the base material is reticular polyester fiber,
the hydrocolloid component is prepared from the following raw materials in parts by weight:
165112 parts of G, 50 parts of vaseline, 15 parts of lanolin, 200 parts of liquid paraffin, 25 parts of sodium carboxymethylcellulose, 8 parts of an anti-inflammatory bacteriostatic agent and 15 parts of a tissue repair agent;
the tissue repair agent consists of allantoin, zinc hyaluronate and calcium hyaluronate according to the weight ratio of 6:3: 1.
The anti-inflammatory bacteriostatic agent consists of glucosamine, sodium ferulate and chitosan according to the weight ratio of 2:3: 7.
The preparation method of the anti-inflammatory and bacteriostatic hydrocolloid oily yarn is the same as that of example 2
Example 4 an anti-inflammatory bacteriostatic hydrocolloid oily yarn
The embodiment provides a hydrocolloid oily yarn, and the concrete scheme is as follows:
a hydrocolloid oily yarn consisting of a substrate and a hydrocolloid component:
the base material is reticular polyester fiber,
the hydrocolloid component is prepared from the following raw materials in parts by weight:
165110 parts of G, 40 parts of vaseline, 10 parts of lanolin, 150 parts of liquid paraffin, 15 parts of sodium carboxymethylcellulose, 5 parts of an anti-inflammatory bacteriostatic agent and 10 parts of a tissue repair agent;
the tissue repair agent consists of allantoin, zinc hyaluronate and calcium hyaluronate according to the weight ratio of 3:5: 3.
The anti-inflammatory bacteriostatic agent consists of glucosamine, sodium ferulate and chitosan according to the weight ratio of 1:7: 9.
The preparation method of the anti-inflammatory and bacteriostatic hydrocolloid oily yarn is the same as that of example 2
Example 5 an anti-inflammatory bacteriostatic hydrocolloid oily yarn
The embodiment provides a hydrocolloid oily yarn, and the concrete scheme is as follows:
a hydrocolloid oily yarn consisting of a substrate and a hydrocolloid component:
the base material is reticular polyester fiber,
the hydrocolloid component is prepared from the following raw materials in parts by weight:
165110 parts of G, 40 parts of vaseline, 10 parts of lanolin, 150 parts of liquid paraffin, 15 parts of sodium carboxymethylcellulose, 5 parts of an anti-inflammatory bacteriostatic agent and 10 parts of a tissue repair agent;
the tissue repair agent consists of allantoin, zinc hyaluronate and calcium hyaluronate according to the weight ratio of 9:2: 1.
The anti-inflammatory bacteriostatic agent consists of glucosamine, sodium ferulate and chitosan according to the weight ratio of 3:2: 4.
The preparation method of the anti-inflammatory and bacteriostatic hydrocolloid oily yarn is the same as that of example 2
Comparative example 1 hydrocolloid oil gauze with anti-inflammatory and bacteriostatic effects
The embodiment provides a hydrocolloid oily yarn, and the concrete scheme is as follows:
a hydrocolloid oily yarn consisting of a substrate and a hydrocolloid component:
the base material is reticular polyester fiber,
the hydrocolloid component is prepared from the following raw materials in parts by weight:
165110 parts of G, 40 parts of vaseline, 10 parts of lanolin, 150 parts of liquid paraffin, 15 parts of sodium carboxymethylcellulose, 5 parts of an anti-inflammatory bacteriostatic agent and 10 parts of a tissue repair agent;
the tissue repair agent consists of allantoin and zinc hyaluronate according to the weight ratio of 2: 1.
The anti-inflammatory bacteriostatic agent consists of glucosamine, sodium ferulate and chitosan according to the weight ratio of 2:3: 7.
The preparation method of the anti-inflammatory and bacteriostatic hydrocolloid oily yarn is the same as that of example 2
The difference from example 2 is that calcium hyaluronate was not added to the tissue repair agent.
Comparative example 2 hydrocolloid oily yarn with anti-inflammation and bacteriostasis functions
The embodiment provides a hydrocolloid oily yarn, and the concrete scheme is as follows:
a hydrocolloid oily yarn consisting of a substrate and a hydrocolloid component:
the base material is reticular polyester fiber,
the hydrocolloid component is prepared from the following raw materials in parts by weight:
165110 parts of G, 40 parts of vaseline, 10 parts of lanolin, 150 parts of liquid paraffin, 15 parts of sodium carboxymethylcellulose, 5 parts of an anti-inflammatory bacteriostatic agent and 10 parts of a tissue repair agent;
the tissue repair agent consists of allantoin and calcium hyaluronate according to the weight ratio of 6: 1.
The anti-inflammatory bacteriostatic agent consists of glucosamine, sodium ferulate and chitosan according to the weight ratio of 2:3: 7.
The preparation method of the anti-inflammatory and bacteriostatic hydrocolloid oily yarn is the same as that of example 2
The difference from example 2 is that zinc hyaluronate was not added to the tissue repair agent.
Comparative example 3 hydrocolloid oil gauze with anti-inflammatory and bacteriostatic effects
The embodiment provides a hydrocolloid oily yarn, and the concrete scheme is as follows:
a hydrocolloid oily yarn consisting of a substrate and a hydrocolloid component:
the base material is reticular polyester fiber,
the hydrocolloid component is prepared from the following raw materials in parts by weight:
165110 parts of G, 40 parts of vaseline, 10 parts of lanolin, 150 parts of liquid paraffin, 15 parts of sodium carboxymethylcellulose, 5 parts of an anti-inflammatory bacteriostatic agent and 10 parts of a tissue repair agent;
the tissue repair agent consists of allantoin, zinc hyaluronate and hyaluronic acid in a weight ratio of 1:1: 1.
The anti-inflammatory bacteriostatic agent consists of glucosamine, sodium ferulate and chitosan according to the weight ratio of 2:3: 7.
The preparation method of the anti-inflammatory and bacteriostatic hydrocolloid oily yarn is the same as that of example 2
The difference from example 2 is that the tissue repair agent consists of allantoin, zinc hyaluronate and calcium hyaluronate in a weight ratio of 1:1: 1.
Comparative example 4 hydrocolloid oil gauze with anti-inflammatory and bacteriostatic effects
The embodiment provides a hydrocolloid oily yarn, and the concrete scheme is as follows:
a hydrocolloid oily yarn consisting of a substrate and a hydrocolloid component:
the base material is reticular polyester fiber,
the hydrocolloid component is prepared from the following raw materials in parts by weight:
165110 parts of G, 40 parts of vaseline, 10 parts of lanolin, 150 parts of liquid paraffin, 15 parts of sodium carboxymethylcellulose, 5 parts of an anti-inflammatory bacteriostatic agent and 10 parts of a tissue repair agent;
the tissue repair agent consists of allantoin, zinc hyaluronate and hyaluronic acid according to the weight ratio of 6:3: 1.
The anti-inflammatory bacteriostatic agent consists of sodium ferulate and chitosan according to the weight ratio of 3: 7.
The preparation method of the anti-inflammatory and bacteriostatic hydrocolloid oily yarn is the same as that of example 2
The difference from the embodiment 2 is that the anti-inflammatory bacteriostat is not added with glucosamine.
Comparative example 5 hydrocolloid oil gauze with anti-inflammatory and bacteriostatic effects
The embodiment provides a hydrocolloid oily yarn, and the concrete scheme is as follows:
a hydrocolloid oily yarn consisting of a substrate and a hydrocolloid component:
the base material is reticular polyester fiber,
the hydrocolloid component is prepared from the following raw materials in parts by weight:
165110 parts of G, 40 parts of vaseline, 10 parts of lanolin, 150 parts of liquid paraffin, 15 parts of sodium carboxymethylcellulose, 5 parts of an anti-inflammatory bacteriostatic agent and 10 parts of a tissue repair agent;
the tissue repair agent consists of allantoin, zinc hyaluronate and hyaluronic acid according to the weight ratio of 6:3: 1.
The anti-inflammatory bacteriostatic agent consists of glucosamine and sodium ferulate according to the weight ratio of 2: 3.
The preparation method of the anti-inflammatory and bacteriostatic hydrocolloid oily yarn is the same as that of example 2
The difference from the embodiment 2 is that the chitosan is not added in the anti-inflammatory bacteriostat.
Comparative example 6 hydrocolloid oil gauze with anti-inflammatory and bacteriostatic effects
The embodiment provides a hydrocolloid oily yarn, and the concrete scheme is as follows:
a hydrocolloid oily yarn consisting of a substrate and a hydrocolloid component:
the base material is reticular polyester fiber,
the hydrocolloid component is prepared from the following raw materials in parts by weight:
165110 parts of G, 40 parts of vaseline, 10 parts of lanolin, 150 parts of liquid paraffin, 15 parts of sodium carboxymethylcellulose, 5 parts of an anti-inflammatory bacteriostatic agent and 10 parts of a tissue repair agent;
the tissue repair agent consists of allantoin, zinc hyaluronate and hyaluronic acid according to the weight ratio of 6:3: 1.
The anti-inflammatory bacteriostatic agent consists of glucosamine, sodium ferulate and chitosan according to the weight ratio of 1:1: 1.
The preparation method of the anti-inflammatory and bacteriostatic hydrocolloid oily yarn is the same as that of example 2
The difference from the example 2 is that the anti-inflammatory bacteriostat consists of glucosamine, sodium ferulate and chitosan according to the weight ratio of 1:1: 1.
Test example I, antibacterial property test
1. Test materials: anti-inflammatory and bacteriostatic hydrocolloid oily yarns prepared in examples 1-5 and comparative examples 1-6.
2. Test subjects: escherichia coli, Candida albicans, Staphylococcus aureus.
3. The test method comprises the following steps: and (3) antibacterial experiment: the 5cm × 5cm anti-inflammatory and bacteriostatic hydrocolloid oily yarns prepared in examples 1-5 and comparative examples 1-6 were placed in a sterile conical flask, and 70mL phosphate buffer (0.03 mol. L) was added-1) And 5mL of bacterial liquid, after the liquid permeates into the culture medium, culturing at 37 ℃ for 24h, and then counting colonies.
The formula for calculating the bacteriostasis rate is as follows: and X is (A-B)/A multiplied by 100 percent, wherein X is the bacteriostasis rate, A is the average colony number of the sample before oscillation, and B is the average colony number of the sample after oscillation.
4. Test results
The test results are shown in table 1.
TABLE 1 hydrocolloid oily yarn antibacterial test for anti-inflammation and bacteriostasis
The results of the antibacterial performance tests in table 1 show that the anti-inflammatory and bacteriostatic hydrocolloid oily gauze prepared in the embodiments 1 to 5 of the present invention has significant inhibitory effects on escherichia coli, candida albicans and staphylococcus aureus, and the bacteriostatic rates after 24 hours contact are all above 97%, wherein the most significant bacteriostatic rate in the embodiment 2 is above 98%, which is the best embodiment of the present invention. The bacteriostatic effects of comparative examples 1 to 6 were relatively weak. The comparative examples 4 to 6 and the comparative examples show that the anti-inflammatory bacteriostatic agent consisting of glucosamine, sodium ferulate and chitosan added in the invention has broad-spectrum and strong antibacterial performance, can effectively prevent the wound from being infected by bacteria, and has high bacteriostatic rate.
Test example two, skin repair force test
1. Test materials: anti-inflammatory and bacteriostatic hydrocolloid oily yarn prepared in groups 1-5 and comparative examples 1-3.
2. Test subjects: 90 female Wistar rats were selected with a body weight of 250 g.
3. The test method comprises the following steps:
90 rats were randomly divided into 9 groups of 10 rats each, examples 1-5, comparative examples 1-3, and blank.
At the beginning of the experiment, 0.25 mL/compound anesthetic (thiamine ketone) was injected into the abdominal cavity to allow the animals to enter a shallow anesthetic state, and then the area of 5cm × 5cm of hair on the back was cut. After the shearing area is disinfected, a square wound surface of 3cm multiplied by 3cm is cut at the middle part of the spine of the back of the mouse by using a surgical knife and is deep to the subcutaneous part, so that a square knife wound surface is formed.
The prepared anti-inflammatory and antibacterial hydrocolloid oily gauze with the size of 3cm multiplied by 3cm is pasted on the wound surface of a rat, and the medicines are replaced at intervals of 3 days until the 9 th day after the wound. The wound size was measured and wound healing recorded when changing dressings.
4. And (3) test results:
the test results are shown in table 2.
TABLE 2 comparison of wound surface area (cm) at different times after injury2)
As can be seen from Table 2, the wound surface area of the blank control group was gradually reduced in examples 1 to 5, comparative examples 1 to 3, as time passed. However, the reduction of the wound area was significantly smaller in the comparative examples 1 to 3 than in the examples 1 to 5. Compared with the wound surface areas of comparative examples 1-3, the differences of the wound surface areas of the test groups in 3 days, 6 days and 9 days have statistical significance (p is less than 0.05), and the observation shows that the granulation tissues grow in the groups of examples 1-5 on the 3 rd day after injury, thin layers or dot-and-ball-shaped epithelia grow on the local part, and the wound edge skin shrinks obviously; on day 9 after the wound, the wound surface was substantially filled with granulation tissue, and the wound margin had seen concentric growth of neoepithelium, whereas the wound surfaces of the comparative examples 1-3 had only a thin layer of granulation, and no obvious neoepithelium was seen. The hydrocolloid oily gauze with the functions of diminishing inflammation and inhibiting bacteria, which is prepared by the invention, can obviously promote wound healing and promote skin tissue regeneration.
The foregoing embodiments are merely illustrative of the principles and utilities of the present invention and are not intended to limit the invention. Any person skilled in the art can modify or change the above-mentioned embodiments without departing from the spirit and scope of the present invention. Accordingly, it is intended that all equivalent modifications or changes which can be made by those skilled in the art without departing from the spirit and technical spirit of the present invention be covered by the claims of the present invention.
Claims (9)
1. The anti-inflammatory and bacteriostatic hydrocolloid oily yarn is characterized by comprising a base material and a hydrocolloid component:
the base material is reticular polyester fiber;
the hydrocolloid comprises the following components in parts by weight: 8-12 parts of thermoplastic elastomer, 30-50 parts of vaseline, 5-15 parts of lanolin, 200 parts of liquid paraffin, 10-25 parts of sodium carboxymethylcellulose, 2-8 parts of anti-inflammatory bacteriostatic agent and 5-15 parts of tissue repair agent.
2. The anti-inflammatory bacteriostatic hydrocolloid oily gauze according to claim 1, characterized in that said tissue repair agent consists of allantoin, zinc hyaluronate and calcium hyaluronate in the weight ratio of (4-9) to (2-5) to (1-3).
3. The anti-inflammatory bacteriostatic hydrocolloid oily yarn of claim 2 wherein said tissue repair agent consists of allantoin, zinc hyaluronate and calcium hyaluronate in a weight ratio of 6:3: 1.
4. The anti-inflammatory bacteriostatic hydrocolloid oily yarn of claim 1 wherein said anti-inflammatory bacteriostatic agent is composed of glucosamine, sodium ferulate and chitosan in the weight ratio of (1-3) to (2-7) to (4-9).
5. The anti-inflammatory bacteriostatic hydrocolloid oily yarn of claim 1 wherein said anti-inflammatory bacteriostatic agent is composed of glucosamine, sodium ferulate and chitosan in a weight ratio of 2:3: 7.
6. An anti-inflammatory bacteriostatic hydrocolloid oily yarn according to claim 1 wherein said thermoplastic elastomer is SEBS.
7. The anti-inflammatory bacteriostatic hydrocolloid oily yarn of claim 1, wherein the hydrocolloid comprises the following components in parts by weight: 10 parts of thermoplastic elastomer, 40 parts of vaseline, 10 parts of lanolin, 150 parts of liquid paraffin, 15 parts of sodium carboxymethylcellulose, 5 parts of anti-inflammatory bacteriostatic agent and 10 parts of tissue repair agent.
8. Hydrocolloid oily yarn according to claim 1, characterized in that the particle size of the sodium carboxymethyl cellulose is between 20 μm and 150 μm.
9. An anti-inflammatory bacteriostatic hydrocolloid oily yarn according to any one of claims 1 to 8, comprising the following steps:
weighing the raw materials according to the weight portion of the hydrocolloid oily yarn of any one of claims 1 to 8;
softening the thermoplastic elastomer, the liquid paraffin, the vaseline and the lanolin for 25-45min at the temperature of 100-200 ℃ to obtain a mixture;
adding the sodium carboxymethylcellulose, the anti-inflammatory bacteriostatic agent and the tissue repair agent into the mixture, mixing and stirring at 90-125 ℃ to obtain a melt, and defoaming in vacuum;
and coating the melt after vacuum defoaming on the base material to obtain the hydrocolloid oily yarn.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011196428.XA CN112245648B (en) | 2020-10-30 | 2020-10-30 | Anti-inflammatory and antibacterial hydrocolloid oily yarn and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011196428.XA CN112245648B (en) | 2020-10-30 | 2020-10-30 | Anti-inflammatory and antibacterial hydrocolloid oily yarn and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112245648A true CN112245648A (en) | 2021-01-22 |
| CN112245648B CN112245648B (en) | 2022-05-17 |
Family
ID=74267566
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011196428.XA Active CN112245648B (en) | 2020-10-30 | 2020-10-30 | Anti-inflammatory and antibacterial hydrocolloid oily yarn and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112245648B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112999201A (en) * | 2021-03-06 | 2021-06-22 | 宁波帕柯斯生物科技有限公司 | Anti-inflammation and antibacterial acne removal patch and preparation method thereof |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009242309A (en) * | 2008-03-31 | 2009-10-22 | Ezaki Glico Co Ltd | Skin care preparation, oral composition, and food and drink |
| WO2013149323A1 (en) * | 2012-04-02 | 2013-10-10 | Ntegrity | Natural products for skin care |
| CN104587518A (en) * | 2015-02-06 | 2015-05-06 | 南京天纵易康生物科技有限公司 | Hyaluronic acid dressing and preparation method thereof |
| CN105833332A (en) * | 2016-06-01 | 2016-08-10 | 北京汉氏联合生物技术股份有限公司 | Composite external use dressing rich in collagen and hyaluronic acid |
| CN107233275A (en) * | 2017-07-06 | 2017-10-10 | 天津杞源堂生物工程有限公司 | A kind of light spot is dispelled yellow fermentation Chinese wolfberry fruit liquid level film and preparation method thereof |
| CN107296784A (en) * | 2017-07-06 | 2017-10-27 | 天津杞源堂生物工程有限公司 | A kind of skin whitening, moisturizing fermentation Chinese wolfberry fruit liquid level film and preparation method thereof |
| CN107308094A (en) * | 2017-07-06 | 2017-11-03 | 天津杞源堂生物工程有限公司 | A kind of salubrious oil-control fermentation Chinese wolfberry fruit liquid level film and preparation method thereof |
| CN108126232A (en) * | 2017-12-29 | 2018-06-08 | 广州润虹医药科技股份有限公司 | Hydrocolloid oil yarn and preparation method thereof |
| CN108543106A (en) * | 2018-06-19 | 2018-09-18 | 珠海市雅莎医疗器械有限公司 | A kind of skin nursing dressing of freckle removing and whitening and preparation method thereof |
| CN110511444A (en) * | 2019-09-04 | 2019-11-29 | 合肥工业大学 | CMC/FA- chitosan hydrochloride composite nanometer particle, preparation method and application |
-
2020
- 2020-10-30 CN CN202011196428.XA patent/CN112245648B/en active Active
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009242309A (en) * | 2008-03-31 | 2009-10-22 | Ezaki Glico Co Ltd | Skin care preparation, oral composition, and food and drink |
| WO2013149323A1 (en) * | 2012-04-02 | 2013-10-10 | Ntegrity | Natural products for skin care |
| CN104587518A (en) * | 2015-02-06 | 2015-05-06 | 南京天纵易康生物科技有限公司 | Hyaluronic acid dressing and preparation method thereof |
| CN105833332A (en) * | 2016-06-01 | 2016-08-10 | 北京汉氏联合生物技术股份有限公司 | Composite external use dressing rich in collagen and hyaluronic acid |
| CN107233275A (en) * | 2017-07-06 | 2017-10-10 | 天津杞源堂生物工程有限公司 | A kind of light spot is dispelled yellow fermentation Chinese wolfberry fruit liquid level film and preparation method thereof |
| CN107296784A (en) * | 2017-07-06 | 2017-10-27 | 天津杞源堂生物工程有限公司 | A kind of skin whitening, moisturizing fermentation Chinese wolfberry fruit liquid level film and preparation method thereof |
| CN107308094A (en) * | 2017-07-06 | 2017-11-03 | 天津杞源堂生物工程有限公司 | A kind of salubrious oil-control fermentation Chinese wolfberry fruit liquid level film and preparation method thereof |
| CN108126232A (en) * | 2017-12-29 | 2018-06-08 | 广州润虹医药科技股份有限公司 | Hydrocolloid oil yarn and preparation method thereof |
| CN108543106A (en) * | 2018-06-19 | 2018-09-18 | 珠海市雅莎医疗器械有限公司 | A kind of skin nursing dressing of freckle removing and whitening and preparation method thereof |
| CN110511444A (en) * | 2019-09-04 | 2019-11-29 | 合肥工业大学 | CMC/FA- chitosan hydrochloride composite nanometer particle, preparation method and application |
Non-Patent Citations (1)
| Title |
|---|
| 王凤山等: "《生化药物研究》", 31 December 1997, 北京：人民卫生出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112999201A (en) * | 2021-03-06 | 2021-06-22 | 宁波帕柯斯生物科技有限公司 | Anti-inflammation and antibacterial acne removal patch and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112245648B (en) | 2022-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109248333B (en) | Medical dressing for resisting bacteria and promoting wound healing and preparation method and application thereof | |
| CN103520764A (en) | Functional dressing, and preparation method and application thereof | |
| JP5460580B2 (en) | Novel active ingredients and their use in fusion | |
| CN107617121B (en) | Biological induction active dressing for skin wound surface and preparation method and application thereof | |
| CN107261200B (en) | Chitosan-nano-laponite composite gel wound dressing and preparation method thereof | |
| Khorasani et al. | The effects of Aloe Vera cream on split-thickness skin graft donor site management: a randomized, blinded, placebo-controlled study | |
| CN1686158A (en) | Adhesive bandage containing hyaluronic acid biological composition | |
| CN112245648B (en) | Anti-inflammatory and antibacterial hydrocolloid oily yarn and preparation method thereof | |
| CN106110369B (en) | A kind of medical composite type hyaluronic acid dressing and preparation method thereof | |
| CN109289079B (en) | Medical dressing for inhibiting scars and preparation method and application thereof | |
| CN108815381B (en) | Traditional Chinese medicine silver titanate composite porous material for burn wound healing and preparation method and application thereof | |
| CN110859989A (en) | Liquid band-aid and preparation method thereof | |
| CN111166932B (en) | Liquid wound spray dressing and preparation method thereof | |
| CN109432483B (en) | Medical dressing for accelerating wound healing and preparation method and application thereof | |
| CN112891615A (en) | Liquid adhesive bandage and preparation method thereof | |
| CN109432479B (en) | Antibacterial hemostatic hydrocolloid oily yarn and preparation method thereof | |
| CN111557790A (en) | Antibacterial and disinfectant nanofiber medical dressing | |
| Morgan | Alginate dressings: part 1: historical aspects | |
| CN113616849B (en) | Liquid dressing for external wound care and preparation method thereof | |
| CN111481733B (en) | Biological medicine wound surface dressing | |
| CN112274687A (en) | Stable hydrocolloid oily yarn and preparation method thereof | |
| CN109276748B (en) | Anti-adhesion healing-promoting antibacterial hydrocolloid dressing and preparation method thereof | |
| CN112121146B (en) | A topical gel for treating skin wound, and its preparation method | |
| RU2312658C1 (en) | Film-forming aerosol for wound protection in treatment and method for its using | |
| CN111729127A (en) | Dressing for wound care and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |